A focused biopharmaceutical company

General presentation for investors and analysts 20 June 2018

In order, among other things, to utilise the 'safe harbour' provisions of the US Private Securities Litigation Reform Act 1995, we are providing the following cautionarystatement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including,among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although we believe our expectations arebased on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that couldcause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at thedate of preparation of this document and AstraZeneca undertakes no obligation to update these forward-looking statements. We identify the forward-lookingstatements by using the words 'anticipates', 'believes', 'expects', 'intends' and similar expressions in such statements. Important factors that could cause actual resultsto differ materially from those contained in forward-looking statements, certain of which are beyond our control, include, among other things: the loss or expiration of,or limitations to, patents, marketing exclusivity or trademarks, or the risk of failure to obtain and enforce patent protection; effects of patent litigation in respect of IPrights; the impact of any delays in the manufacturing, distribution and sale of any of our products; the impact of any failure by third parties to supply materials orservices; the risk of failure of outsourcing; the risks associated with manufacturing biologics; the risk that R&D will not yield new products that achieve commercialsuccess; the risk of delay to new product launches; the risk that new products do not perform as we expect; the risk that strategic alliances and acquisitions, includinglicensing and collaborations, will be unsuccessful; the risks from pressures resulting from generic competition; the impact of competition, price controls and pricereductions; the risks associated with developing our business in emerging markets; the risk of illegal trade in our products; the difficulties of obtaining and maintainingregulatory approvals for products; the risk that regulatory approval processes for biosimilars could have an adverse effect on future commercial prospects; the risk offailure to successfully implement planned cost reduction measures through productivity initiatives and restructuring programmes; the risk of failure of critical processesaffecting business continuity; economic, regulatory and political pressures to limit or reduce the cost of our products; failure to achieve strategic priorities or to meettargets or expectations; the risk of substantial adverse litigation/government investigation claims and insufficient insurance coverage; the risk of substantial productliability claims; the risk of failure to adhere to applicable laws, rules and regulations; the risk of failure to adhere to applicable laws, rules and regulations relating toanti-competitive behaviour; the impact of increasing implementation and enforcement of more stringent anti-bribery and anti-corruption legislation; taxation risks;exchange rate fluctuations; the risk of an adverse impact of a sustained economic downturn; political and socio-economic conditions; the risk of environmentalliabilities; the risk of occupational health and safety liabilities; the risk associated with pensions liabilities; the impact of failing to attract and retain key personnel and tosuccessfully engage with our employees; the risk of misuse of social medial platforms and new technology; and the risk of failure of information technology andcybercrime. Nothing in this presentation / webcast should be construed as a profit forecast.

2

Forward-looking statements

3

Strategic priorities

Achieve scientific leadership

1Return to growth

2Be a great place to work

3

Scientific collaborations key driver behind move

4

New Cambridge, UK R&D centre and HQ

Three therapy areas

5

Focused strategy

RespiratoryCardiovascular, Renal & MetabolismOncology

Commitment to further focus the portfolio

A new AstraZeneca with science-based culture

6

R&D productivity: Sustainable progress

Source: Internal analysis. High-impact (rating > 15); medium-impact (rating > 5); other (rating < 5).

AstraZeneca (AZN) and industry peers/competitors (CP) 1-7.Source: Internal analysis based on focr.org. Includes Breakthrough TherapyDesignations (BTD) in the three main AstraZeneca therapy areas.

FDA BTDs granted in AZN’s main therapy areas 2016-2017

Scientific publicationsHigh-impact publications

Other publicationsMedium-impact publications

5 5 5

4

2 2 2 2

Sustainable level of potential new medicines in Phase II trials

1,054

397

27

3533

3634

OncologyRespiratory

CVRMOther

Unprecedented activity level in ‘17

7

Late-stage pipeline news flow

Tagrissolung cancer (AURA3)Full approval (US, EU)

Forxigatype-2 diabetesApproval (CN)

Qterntype-2 diabetesApproval (US)

Tagrissolung cancer

Approval (CN)

Siliqpsoriasis

Approval (US, by partner)

Lynparzabreast cancer

Phase III positive

Farxigatype-2 diabetes

CVD-REAL study

inebilizumabneuromyelitis opticaspectrum disorder

Orphan designation (EU)

Lynparzaovarian cancerOrphan Drug

designation (JP)

Imfinzibladder cancerApproval (US)

Faslodexbreast cancer 1LApproval (EU, JP)

Kyntheumpsoriasis

Approval (EU, by partner)

Imfinzilung cancer (PACIFIC)

Phase III positive (PFS3)

Bydureontype-2 diabetes (CVOT)

Phase III met primary safety objective; did not meet primary

efficacy objective

Imfinzilung cancer (MYSTIC)

Phase III negative (PFS)

Faslodexbreast cancerApproval (US)

Lynparzaovarian cancer 2L, 4L/tablets

Approval (US)

Calquencemantle cell lymphoma

Approval (US)

Briliqueprior myocardial infarction

Approval (CN)

Farxiga + Bydureontype-2 diabetes

Approval (US, EU)

Bydureon BCisetype-2 diabetes autoinjector

Approval (US)

SymbicortCOPD exacerbations

Approval (US)

tralokinumabsevere, uncontrolled asthma

Phase IIIs negative

Tagrissolung cancer (FLAURA)

Phase III positive

moxetumomabhairy cell leukaemiaPhase IIIs positive

DuaklirCOPD

Phase III positive

Tagrissolung cancer (FLAURA)Breakthrough Therapy

Designation (US)

Imfinzilung cancer (PACIFIC)Breakthrough Therapy

Designation (US)

roxadustatanaemia

Completed reg. submission (CN, by partner)

tezepelumabsevere, uncontrolled

asthmaPhase IIb positive

Farxigatype-1 diabetes

Phase IIIs positive

Calquencemantle cell lymphomaBreakthrough Therapy

Designation (US)

Lynparzaovarian cancer 2LReg. submission

(EU, JP)

Lynparzabreast cancer

Reg. submission (US, JP)

ZS-9hyperkalaemia

Complete Response (US)

ZS-9hyperkalaemia

CHMP1 opinion (EU)

Imfinzilung cancer (PACIFIC)

Reg. submission (US, EU, JP)

BevespiCOPD2

Reg. submission (EU)

Bydureon BCisetype-2 diabetes autoinjector

Reg. submission (EU)

Fasenrasevere, uncontrolled asthma

CHMP opinion (EU)

Fasenrasevere, uncontrolled asthma

Approval (US)

Significant patient benefits anticipated to support return to growthRegulatory actions

Data & designations

Tagrissolung cancer (FLAURA)

Reg. submission (EU, JP)

1. The Committee for Medicinal Products for Human Use.2. Chronic obstructive pulmonary disease.1. Progression-free survival.Status as of 14 December 2017. Favourable / unfavourable news.

benralizumabsevere, uncontrolled asthmaRegulatory submission (JP)

Significant opportunities exist in all three therapy areas

8

Late-stage pipeline and key lifecycle medicines

1. Lifecycle development programme.2. Under regulatory review in major jurisdiction.Status as of 20 June 2018.

Oncology Cardiovascular,Renal & Metabolism Respiratory

Lynparza1, 2

multiple cancersroxadustat2

anaemiaPT010

COPD / asthma

Tagrisso1, 2

lung cancertezepelumab

severe, uncontrolled asthma

Imfinzi1, 2

multiple cancers

Calquence1

blood cancers Other

moxetumomab pasudotox2

leukaemiaanifrolumab

lupus

tremelimumabmultiple cancers

selumetinibthyroid cancer

savolitinibkidney cancer

9

Full pipeline of new medicines (NMEs)

Status as of 18 May 2018.

1 Includes significant fixed-dose combination projects, and parallel indications that are in a separate therapy area.# Partnered and/or in collaboration; ¶ Registrational Phase II/III study.

Oncology RespiratoryCardiovascular, Renal & Metabolism Other

Phase I Phase II Phase III31 New Molecular Entities 21 New Molecular Entities 8 New Molecular Entities

Small molecule Small molecule Small moleculeLarge molecule Large molecule Large molecule

Applications Under Review2 New Molecular Entities

Large moleculeSmall molecule

AZD0156ATM solid tumours

AZD1390ATM healthy volunteer study

AZD2811#Aurora solid tumours

AZD4573CDK9 hematalogical malignancies

AZD4635A2aR inhibitor solid tumours

AZD4785KRAS solid tumours

AZD5153BRD4 solid tumours

AZD5991MCL1 hematalogical malignancies

AZD6738ATR solid tumours

AZD8186PI3Kβ solid tumours

AZD9496SERD ER+ breast

MEDI0562#hOX40 solid tumours

MEDI1873GITR solid tumours

MEDI3726#PSMA prostate

MEDI4276HER2 solid tumours

MEDI5083CD40 ligand fusion protein solid tumours

MEDI7247antibody drug conjugate haems

MEDI9197#TLR 7/8 solid tumours

oleclumabCD73 solid tumours

adavosertib# (AZD1775)+chemotherapyWee1+chemo ovarian cancer

AZD4547FGFR solid tumours

capivasertib (AZD5363)#AKT breast cancer

vistusertibmTOR 1/2 solid tumours

Imfinzi#+tremelimumab MYSTICPD-L1+CTLA-4 1L NSCLC

Lynparza¶+cediranib CONCERTOPARP+VEGF recurrent Pt-R ovarian

savolitinib# SAVOIRMET pRCC

selumetinib ASTRAMEK differentiated thyroid cancer

moxetumomab pasudotox# PLAITCD22 3L HCL

MEDI7219anti-diabetic type-2 diabetes

AZD5718FLAP coronary artery disease

AZD8601#VEGF-A cardiovascular

MEDI0382GLP-1/glucagon type-2 diabetes

MEDI5884#cholesterol modulation cardiovascular

MEDI6012LCAT cardiovascular

verinuradURAT-1 chronic kidney disease

roxadustat# HIFPH anaemia CKD/ESRD

MEDI3506IL-33 COPD

abediterol#LABA asthma/COPD

AZD1419#inhaled TLR9 asthma

AZD7594Inhaled SGRM asthma/COPD

AZD7986#DPP1 COPD

AZD8871#MABA COPD

AZD9567SGRM RA/respiratory

tezepelumab# NAVIGATOR SOURCETSLP severe uncontrolled asthma

MEDI0700#BAFF/B7RP1 SLE

MEDI1341alpha synuclein parkinson's disease

MEDI1814#amyloidβ alzheimer's disease

MEDI7352NGF/TNF osteoarthritis pain

MEDI3902Psl/PcrV Pseudomonas pneumonia

MEDI8852influenza A treatment

MEDI8897#passive RSV prophylaxis

prezalumab#primary Sjögren’s syndrome

suvratoxumabα-Toxin Staphylococcus pneumonia

anifrolumab# TULIPType I IFN receptor SLE

AZD4831MPO HFpEF

AZD9977MCR cardiovascular

AZD1402#inhaled IL-4Ra asthma

AZD5634inhaled ENaC cystic fibrosis

AZD7594+abediterol#Inhaled SGRM+LABA asthma/COPD

AZD0284RORg psoriasis/respiratory

lanabecestat#BACE early alzheimer's disease

PT010LABA/LAMA/ICS COPD

Unlocking and realising potential of new medicine

10

Late-stage pipeline news flow 2018 & 2019

Q2 2018 H2 2018 2019Regulatory decision Tagrisso - lung cancer (EU)

Lokelma - hyperkalaemia (US)Lynparza - breast cancer (JP)Tagrisso - lung cancer (JP)Imfinzi - lung cancer (PACIFIC) (EU, JP)moxetumomab pasudotox - HCL 3L (US)Bydureon autoinjector - type-2 diabetes (EU)Bevespi - COPD (EU)

Lynparza - breast cancer (EU)

Regulatory submission Duaklir - COPD (US) Bevespi - COPD (JP)Lynparza - ovarian cancer 1LImfinzi +/- treme- lung cancer (MYSTIC) - head & neck cancer 2L (EAGLE)selumetinib - thyroid cancer

PT010 - COPDFasenra - COPD

Lynparza - pancreatic cancerImfinzi + treme - lung cancer 1L (NEPTUNE)Imfinzi +/- treme- lung cancer (POSEIDON)- small-cell lung cancer (CASPIAN)- bladder cancer 1L (DANUBE)- head & neck cancer 1L (KESTREL)Calquence - chronic lymphocytic leukaemiaBrilinta - CAD2/type-2 diabetes CVOTFarxiga - type-2 diabetes CVOT (DECLARE)roxadustat - anaemia (US)anifrolumab - lupus

Key Phase III data readouts

Lynparza - ovarian cancer 1L

Fasenra - COPD (TERRANOVA)

Imfinzi +/- treme- lung cancer (MYSTIC) (final OS)- head & neck cancer 2L (EAGLE)- head & neck cancer 1L (KESTREL)selumetinib - thyroid cancer

Farxiga - type-2 diabetes CVOT1 (DECLARE)roxadustat - anaemia

anifrolumab - lupus

Lynparza - pancreatic cancerImfinzi - lung cancer (PACIFIC) (final OS)Imfinzi + treme - lung cancer 1L (NEPTUNE)Imfinzi +/- treme- lung cancer (POSEIDON)- small-cell lung cancer (CASPIAN)- bladder cancer 1L (DANUBE)Calquence - chronic lymphocytic leukaemiaBrilinta - CAD/type-2 diabetes CVOTFarxiga - heart failurelanabecestat - Alzheimer’s disease

1. Cardiovascular outcomes trial.2. Coronary artery disease.Status as of 18 May 2018.

Momentum to improve during the year

11

2018: return to growth on track

2018: low single-digit growth in Product Sales

Lynparzaongoing launch of tablet in ovarian and breast cancer

Tagrissoongoing launch in

1st-line lung cancer

Imfinziongoing launch in

unresect. sIII lung cancer

Brilintacontinued

global growth

Farxigacontinued global growthand the DECLARE trial

Crestorannualisation of

loss of exclusivity(EU, JP)

Fasenraongoing launch in

severe, uncontrolled asthma

Change (Product Sales growth) and 2018 guidance at CER.

Medicines that are impactingProduct Sales growth in 2018

Q1 impacted by Crestor EU/JP; divestmentsComparisons easing as the year progresses

FY 2010

FY 2011

FY 2012

FY 2013

FY 2014

FY 2015

FY 2016

Q1 2017

Q2 2017

Q3 2017

Q4 2017

Q1 2018

Prod

uct S

ales

gro

wth B

MS

D

iabe

tes

Alli

ance

Q1 2018 $m % change % Product

Sales

Product Sales 4,985 (2) 100

Oncology 1,230 33 25

New CVRM 900 8 18

Respiratory 1,181 (6) 24

Other 1,674 (19) 34

Emerging Markets 1,765 8 35

-of which China 1,025 22 21

Overall performance impacted by Crestor EU / JP, divestments

12

Product Sales: Oncology, China were the key drivers

Product Sales values at actual exchange rates; change at CER.

R&D productivity & focus drive decisions

13

Strategic value-creation framework

R&D productivityFocus on three main therapy

areas

‘Following the science’leads to innovationin and outside areas offocus

OncologyCVRM - Cardiovascular,Renal & MetabolismRespiratory

Externalisation1(milestones/royalty)

Accelerate/enhance value; or new medicines outside focus

Product Sales(Including Growth Platforms)

Other Operating Income2

Disposal, typically of legacy medicines outside focus

1. Medicines in which AstraZeneca maintains a significant future interest. Income through (recurring) milestones and royalty.2. One-off disposal income and legacy royalty income.

Geographic platform for growth

15

Emerging Markets

US31% ofProduct Sales

Europe24% of

Product Sales

Rest of World

Established(ex-Japan)

4% ofProduct Sales

Japan11% of

Product Sales

Emerging Markets

(ex-China)16% of

Product Sales

China15% of

Product Sales

2017 Product Sales as reported.

Primary care key to success

16

Emerging Markets

51%

49%Europe

$42-49bn growth

9%

91%AFME

$15-20bn growth

6%

94%

Latin America$20-25bn

growth

32%68%

North America$185-215bn

growth

40%60% World

$305-335bn growth

15%

85%

Asia$70-90bn

growth

Primary care

Specialty care

Share of absolute growth 2016-2021 by region, specialty and primary careSource: IMS Market Prognosis, September 2016; QuintilesIMS Institute, October 2016.Chart notes: Growth in US$ using constant exchange rates. Asia: China, India, Russia, CIS states, SE Asia, Oceania and Japan. AFME: Africa and Middle East.

Q1 2018$m % change % Total

Revenue

Total Revenue 5,178 (9) 100

- Product Sales 4,985 (2) 96

- Externalisation Revenue 193 (67) 4

Gross Margin 78.8% (4) pp -

Operating Expenses 3,349 (1) 65

- R&D Expenses 1,240 (12) 24

- SG&A Expenses 2,028 6 39

Other Operating Inc. & Exp. 124 (64) 2

Tax Rate 18% - -

EPS $0.48 (51) -

Absolute values at actual exchange rates; change at CER.Gross Margin reflects Gross Profit derived from Product Sales, divided by Product Sales.

17

Core Profit & Loss

As a company built on delivering positive health outcomes, sustainability underpins everything AstraZeneca does

19

Sustainability

• As we strive to reach 200 million patients by 2025, we are evolving our approach and in 2017 rolled out a roadmap that further embedded sustainability into the Company’s DNA

• This will ensure AstraZeneca effectively addresses the most fundamental issues for business, shareholders, society and the environment

20

Sustainability - recent highlights

Healthy Heart Africa Program: Over one million patients screened in 2015, exceeding its year-one target

Achieved a 21.2% cut in our greenhouse gas footprint from 2010 levels

Increased the number of senior managers who are women to 42%

100% of employees trained on Code of Conduct

#2 Overall in Pharmaceuticals, Biotechnology and Life Sciences industry group#1 in sector: Health Outcomes Contribution, Marketing Practices, Climate Strategy

Discovery, development and commercial structure

21

Great place to work

GlobalMedicines

Development Market

Innovative Medicines and Early Development Biotech Unit

(AstraZeneca Researchand Early Development)

MedImmune Biotech Unit(MedImmune Research and Early Development

Late-stagedevelopmentDiscovery and early development

Collaborations and combinations

Internal and external

opportunities

Commercial

GlobalPortfolio

&ProductStrategy

22

Great place to work

Headquarters

Gothenburg, Sweden Gaithersburg, USCambridge, UK

Strategic R&D Centre Strategic R&D Centre

Realising company vision

23

Great place to work

1. A passion for people development

6. Access to medicines & social responsibility

5. Environmental sustainability

4. Energising sites and workplaces

3. Flawless technologyand ways of working

2. Strong, supportive, leadership at all levels

Values and Purpose

External recognitions

24

Great place to work

• Financials on track• Product Sales as anticipated

– Strong execution of launches; offset by tail of Crestor EU/JP and divestments• Total Revenue impacted by lower Initial Externalisation Revenue• Core operating expenses declined by 1%

• Newer medicines delivered $0.4bn in additional sales vs. Q1 2017 and 66% growth• Lynparza, Tagrisso, Imfinzi all very strong• CVRM blockbusters Brilinta and Farxiga continued growth• Respiratory competitive, but Fasenra off to a rapid start• China maintained fast growth

• Pipeline continued to deliver important news flow

• 2018 guidance reiterated

Financials on track - commercial execution - guidance reiterated

25

Encouraging launches underpin 2018 return to growth

Absolute values, change and guidance all at CER.

26

On track: Long-term goals

>$45bn in 2023

2012-2014Building strong

foundations

2018+Sustainable delivery

and growth

2015-2017Delivering on return

to growth

Target is at constant exchange rates (2013) which is equivalent to ~$40bn at current exchange rates.

astrazeneca.com/investors

Thomas Kudsk LarsenCambridge, UKthomas.larsen@astrazeneca.comT: +44 20 3749 5712M: +44 7818 524185

Mitchell ChanWashington D.C., USmitchell.chan@astrazeneca.com+1 240 477 3771Toll free +1 866 381 7277

Nick StoneCambridge, UKnick.stone@astrazeneca.comT: +44 20 3749 5716 M: +44 7717 618834

Craig MarksCambridge, UKcraig.marks@astrazeneca.comT: +44 20 3749 5714M: +44 7881 615764

Henry WheelerCambridge, UKhenry.wheeler@astrazeneca.comT: +44 20 3749 5797M: +44 7788 354619

Christer GruvrisCambridge, UKchrister.gruvris@astrazeneca.comT: +44 20 3749 5711 M: +44 7827 836825

27

Investor Relations

Use of AstraZeneca webcast, conference call and presentation slidesThe AstraZeneca webcast, conference call and presentation slides (together the ‘AstraZeneca Materials’) are for your personal, non-commercial use only. You may not copy, reproduce, republish, post, broadcast,transmit, make available to the public, sell or otherwise reuse or commercialise the AstraZeneca Materials in any way. You may not edit, alter, adapt or add to the AstraZeneca Materials in any way, nor combine theAstraZeneca Materials with any other material. You may not download or use the AstraZeneca Materials for the purpose of promoting, advertising, endorsing or implying any connection between you (or any thirdparty) and us, our agents or employees, or any contributors to the AstraZeneca Materials. You may not use the AstraZeneca Materials in any way that could bring our name or that of any Affiliate into disrepute orotherwise cause any loss or damage to us or any Affiliate. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA. Telephone + 44 20 3749 5000, www.astrazeneca.com

Jen KretzmannCambridge, UKjennifer.kretzmann@astrazeneca.comT: +44 xx xxxx xxxx M: +44 7469 408333